Dr. Addington and Colleagues reply to Methodological Issues in a Comparative Study of Ziprasidone and Risperidone Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We appreciate the interest in our research shown by Dr. Gharabawi and the medical affairs team at Janssen Pharmaceutica.

Dr. Gharabawi and colleagues have raised 2 main points: risperidone dose and selection of the population for evaluation of efficacy and safety. Mean total daily doses were 7.4 mg and 114.2 mg for risperidone and ziprasidone, respectively.¹‘ ‹